These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 38626563)
1. Efficacy of Esketamine among patients with treatment resistant depression in a 'real world' health-care setting in Israel. Dvorak L; Bloemhof-Bris E; Shelef A; Halperin D; Wexler G; Talmon O; Feffer K J Psychiatr Res; 2024 Jun; 174():66-72. PubMed ID: 38626563 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. Kryst J; Kawalec P; Pilc A Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783 [No Abstract] [Full Text] [Related]
5. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]
6. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. Samalin L; Rothärmel M; Mekaoui L; Gaudré-Wattinne E; Codet MA; Bouju S; Sauvaget A Int J Psychiatry Clin Pract; 2022 Nov; 26(4):352-362. PubMed ID: 35174754 [TBL] [Abstract][Full Text] [Related]
7. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data. Nijs M; Wajs E; Aluisio L; Turkoz I; Daly E; Janik A; Borentain S; Singh JB; DiBernardo A; Wiegand F Int J Neuropsychopharmacol; 2020 Jul; 23(7):426-433. PubMed ID: 32270176 [TBL] [Abstract][Full Text] [Related]
8. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024 [TBL] [Abstract][Full Text] [Related]
9. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080 [TBL] [Abstract][Full Text] [Related]
10. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients. Banov MD; Landrum RE; Moore MB; Szabo ST J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009 [TBL] [Abstract][Full Text] [Related]
11. Long-term remission following esketamine nasal spray sessions in a patient with severe and highly treatment-resistant depression: a single-case report. Arrighi L; Maakaron E; Korchia T; Lançon C; Richieri R Int Clin Psychopharmacol; 2024 Sep; 39(5):323-325. PubMed ID: 37551607 [TBL] [Abstract][Full Text] [Related]
12. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. Chiappini S; d'Andrea G; De Filippis S; Di Nicola M; Andriola I; Bassetti R; Barlati S; Pettorruso M; Sensi S; Clerici M; Dell'Osso B; Vita A; Martinotti G Eur Neuropsychopharmacol; 2023 Sep; 74():15-21. PubMed ID: 37148637 [TBL] [Abstract][Full Text] [Related]
13. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States. Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis. Seshadri A; Prokop LJ; Singh B J Affect Disord; 2024 Jul; 356():379-384. PubMed ID: 38537759 [TBL] [Abstract][Full Text] [Related]
15. Intranasal esketamine: A novel drug for treatment-resistant depression. Khorassani F; Talreja O Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review. Capuzzi E; Caldiroli A; Capellazzi M; Tagliabue I; Marcatili M; Colmegna F; Clerici M; Buoli M; Dakanalis A Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502248 [TBL] [Abstract][Full Text] [Related]
18. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Ionescu DF; Fu DJ; Qiu X; Lane R; Lim P; Kasper S; Hough D; Drevets WC; Manji H; Canuso CM Int J Neuropsychopharmacol; 2021 Jan; 24(1):22-31. PubMed ID: 32861217 [TBL] [Abstract][Full Text] [Related]
19. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants. Singh JB; Fedgchin M; Daly EJ; Drevets WC Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. Papakostas GI; Salloum NC; Hock RS; Jha MK; Murrough JW; Mathew SJ; Iosifescu DV; Fava M J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]